JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri: STRATIFY-2 First published 29/03/2019 Last updated 02/07/2024 EU PAS number:EUPAS28923 Study Finalised